title: Management of stage I nonseminomatous germ-cell tumors.
abstract: Following orchiectomy in patients with stage 1 nonseminomatous germ-cell tumors (NSGCT), there are three treatment options. Retroperitoneal lymph-node dissection (RPLND) is currently the treatment of choice in the United States and can be both diagnostic and therapeutic but is associated with surgical morbidities. Surveillance is the least invasive but carries the highest potential for relapse and can be timely and costly for both patient and physician. Primary chemotherapy avoids the morbidity of surgery while achieving similar survival rates, albeit with potentially significant side effects. The advantages and disadvantages of each treatment modality are discussed.
authors.affiliation: Department of Hematology and Oncology, Taussig Cancer Center, and Genitourinary Oncology Program, Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
authors.forename: John
authors.initials: J
authors.lastname: Thomas
authors.forename: Michael
authors.initials: M
authors.lastname: Aleman
authors.forename: Robert
authors.initials: R
authors.lastname: Dreicer
authors.forename: Eric A
authors.initials: EA
authors.lastname: Klein
mesh_terms: D018237:Germinoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods; D008297:Male; D008991:Monitoring, Physiologic; D012187:Retroperitoneal Space; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*